title: Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
authors.affiliation: Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy; Italian Nephro-Oncology Group (Gruppo Italiano di Oncologia Nefrologica - G.I.O.N.), Italy. Electronic address: c.porta@smatteo.pv.it.
authors.forename: Camillo
authors.initials: C
authors.lastname: Porta
authors.affiliation: Radiology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Vercelli
authors.affiliation: Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy; Italian Nephro-Oncology Group (Gruppo Italiano di Oncologia Nefrologica - G.I.O.N.), Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Paglino
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000068338:Everolimus; D000077157:Sorafenib; D020123:Sirolimus